PMCT联合TACE治疗中晚期肝癌

目的 探讨经肝动脉栓塞化疗(TACE)联合超声引导微波凝固(PMCT)治疗中晚期肝癌的疗效.方法 22例单纯行TACE(对照组)、18例行TACE联合PMCT综合治疗肝癌(治疗组),对两组疗效进行分析.结果 临床CT复查,瘤体变化对照、对照组及治疗组有效率分别为68.3%和83.4%;彩超示血流信号减少率为59%和83%;0.5、1.0、1.5、2.0年生存率对照组依次为50%、27.3%、0、0,治疗组依次为66.7%、24.4%、16.7%、5.6%,中位生存率和中位生存期分别为5.7月和9.6月,1.5、2.0年生存率和中位生存期均有显著差异,治疗组AFP水平明显降低.结论 TACE联合PMCT可提高中晚期肝癌近期疗效,显著提高1.5、2.0年生存率,延长生存期.

Clinical Observation of Curative Effect of PMCT Combined with TACE on Moderate or Advanced Hepatocellular Carcinoma

Objective To evaluate the curative effect of percutaneous microwave coagulation therapy (PMCT) combined with transcatheter arterial chemoembolization (TACE) on moderate or advanced hepatocellular carcinoma. Methods Of 40 patients with moderate or advanced hepatic carcinoma, 18 were treated by PMCT combined with TACE (treatment group) and 22 merely by TACE (control group). The curative effects were compared between both the groups. Results The effective rates in the treatment and control groups were 83.4% and 68.3% respectively. Color ultrasound showed that the reduction rate of blood supply for the tumor in the treatment and control groups were 83.0% and 59.0% respectively. The survival rates of 0.5, 1.0, 1.5, 2.0 years were 50%, 27.3%, 0% and 0% respectively in the control group, and 66.7%, 24.4%, 16.7% and 5.6% respectively in the treatment group. The median survival time in the treatment and control groups was 9.6 and 5.7 months respectively. There were significant differences in 1.5 and 2.0 years survival rate and the median survival time between both the groups (P<0.05). The blood level of alpha fetoprotein was significantly lower in the treatment group than that in the control group (P<0.05). Conclusion PMCT Combined with TACE can enhance the curative effect on hepatocellular carcinoma.